Frazier Lifesciences Acquisition Corporation Stock
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.97 EUR | +0.73% | -0.09% | +96.69% |
Sales 2024 * | 10.78M 11.6M | Sales 2025 * | 9.04M 9.72M | Capitalization | 1.82B 1.96B |
---|---|---|---|---|---|
Net income 2024 * | -160M -172M | Net income 2025 * | -133M -143M | EV / Sales 2024 * | 169 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 202 x |
P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
-14.7
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.23% |
1 day | +0.73% | ||
1 week | -0.09% | ||
Current month | +0.73% | ||
1 month | +2.62% | ||
3 months | +12.38% | ||
6 months | +112.89% | ||
Current year | +96.69% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 21.82 | -3.32% | 144,688 |
24-05-02 | 22.57 | +2.73% | 136,067 |
24-05-01 | 21.97 | +0.73% | 267,729 |
24-04-30 | 21.81 | +0.69% | 42,283 |
24-04-29 | 21.66 | -1.50% | 196,498 |
End-of-day quote Nasdaq, May 30, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.69% | 1.96B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- NAMS Stock